Evidence map›Paper›PMID 31448368›Full record

ArticleFuture drug discovery2019

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer.

Vidhi Khanna, Stephen Kalscheuer, Ameya Kirtane, Wenqiu Zhang, Jayanth Panyam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future drug discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Cancer stem cells and strategies for targeted drug delivery.Drug delivery and translational research · 2021
    Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vidhi KhannaDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Stephen KalscheuerDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Ameya KirtaneDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Wenqiu ZhangDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Jayanth PanyamDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
University of Minnesota · US

Funding

Cancer Stem Cell-Targeted, Silicate Prodrug Nanoparticles to Combat RecurrenceR01EB019893 · NIBIB · UNIVERSITY OF MINNESOTA · PI HOYE, THOMAS R., PANYAM, JAYANTH · 2017 to 2020
$1.3M
NIBIB NIH HHS R01 EB019893
6 · The paper itself

Abstract

aimWe previously developed two antibodies that bind to a cell surface protein, perlecan, overexpressed in triple-negative breast cancer (TNBC). The goal of this study was to investigate these antibodies as targeting ligands for nanoparticle-mediated drug delivery.

methodsPaclitaxel-loaded poly(D,L-lactide-co-glycolide) nanoparticles were functionalized with antibodies using thiol-maleimide chemistry. Effect of antibody functionalization on therapeutic efficacy of drug-loaded nanoparticles was investigated using

resultsThe antibodies were covalently conjugated to nanoparticles without affecting antibody binding affinity or nanoparticle properties. Perlecan-targeted nanoparticles showed improved cell uptake, retention, cytotoxicity

conclusionThe data presented here indicates that perlecan-targeted nanoparticles can improve tumor drug delivery to TNBC.

Indexed as

antibodyperlecanpolymeric nanoparticlestargeted drug deliverytriple-negative breast cancer

Identifiers

PMID31448368
PMCPMC6700713
OpenAlexW2954930978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.